Basic Information
-
Brand Name: Pari CR 37.5 Tablet
-
Type: Antidepressant / Anti-Anxiety (SSRI – Selective Serotonin Reuptake Inhibitor)
-
Form: Controlled Release (CR) Tablet
-
Pack Size: Strip of 10 tablets (commonly available)
-
Manufacturer / Marketer: Ipca Laboratories Ltd.
Composition (per tablet)
-
Paroxetine Hydrochloride – 37.5 mg (Controlled Release)
Uses / Indications
Pari CR 37.5 Tablet is prescribed in psychiatry for the treatment of:
-
Major Depressive Disorder (MDD)
-
Generalized Anxiety Disorder (GAD)
-
Obsessive-Compulsive Disorder (OCD)
-
Panic Disorder & Social Anxiety Disorder (Social Phobia)
-
Post-Traumatic Stress Disorder (PTSD)
-
Premenstrual Dysphoric Disorder (PMDD)
Mechanism of Action
-
Paroxetine (SSRI):
-
Increases serotonin levels in the brain by blocking its reuptake
-
Improves mood, reduces anxiety, helps control obsessive thoughts & panic attacks
-
-
CR (Controlled Release): Releases medicine gradually → ensures once-daily dosing with better tolerability
Dosage & Administration
-
Adults: Typically 37.5 mg once daily, as prescribed by psychiatrist
-
Take preferably in the morning with food
-
Swallow whole – do not crush or chew (to maintain controlled release)
-
Stopping should be gradual → tapering required (to avoid withdrawal symptoms)
Side Effects
-
Common: nausea, headache, dizziness, drowsiness, sweating, constipation, dry mouth
-
Sexual side effects: reduced libido, delayed ejaculation, difficulty in orgasm
-
Rare: weight gain, tremors, blurred vision, agitation
-
Severe (rare): suicidal thoughts (especially in young adults during early treatment)
Precautions & Warnings
-
Use strictly under psychiatrist’s prescription
-
Avoid abrupt discontinuation – taper slowly
-
Caution in patients with bipolar disorder, seizures, severe liver/kidney disease
-
Avoid alcohol (increases sedation & side effects)
-
Drug interactions: MAO inhibitors, anticoagulants, other antidepressants, antipsychotics
-
Pregnancy & breastfeeding: use only if clearly prescribed
Reviews
There are no reviews yet.